PDCD1 and melanoma: Likewise, anti-PD-1 therapies (pembrolizumab and nivolumab) have also shown anti-tumor efficacy in advanced NSCLC, melanoma, head and neck cancer, metastatic cervical cancer (66), and renal cell carcinoma with reports of rapid and durable tumor regression in some cancers (67–69).